Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Re­searchers still have key ques­tions about Ei­sai’s in­ves­ti­ga­tion­al Alzheimer’s drug lecanemab fol­low­ing the pub­li­ca­tion of more Phase III da­ta in the New Eng­land Jour­nal of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER